Jpmorgan Chase & CO Viking Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,251,671 shares of VKTX stock, worth $122 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,251,671

Previous 1,040,158 116.47%

Holding current value

$122 Million

Previous $85.3 Million 39.94%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$47.39 - $80.2 $57.4 Million - $97.2 Million	1,211,513 Added 116.47%	2,251,671 $119 Million
Q1 2024 May 10, 2024	BUY	$17.4 - $94.5 $8.22 Million - $44.7 Million	472,566 Added 83.26%	1,040,158 $85.3 Million
Q4 2023 Feb 12, 2024	BUY	$9.24 - $19.64 $96,317 - $204,727	10,424 Added 1.87%	567,592 $10.6 Million
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $116,134 - $170,160	10,635 Added 1.95%	557,168 $6.17 Million
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $8.07 Million - $13.5 Million	543,895 Added 20617.7%	546,533 $8.86 Million
Q1 2023 May 11, 2023	BUY	$8.08 - $17.33 $17,291 - $37,086	2,140 Added 429.72%	2,638 $43,000
Q4 2022 Feb 13, 2023	SELL	$2.72 - $9.4 $77,547 - $267,994	-28,510 Reduced 98.28%	498 $4,000
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $43,546 - $66,429	-17,077 Reduced 37.06%	29,008 $80,000
Q2 2022 Aug 11, 2022	BUY	$2.11 - $3.15 $27,835 - $41,554	13,192 Added 40.11%	46,085 $134,000
Q1 2022 May 11, 2022	BUY	$3.0 - $4.88 $16,818 - $27,357	5,606 Added 20.54%	32,893 $99,000
Q4 2021 Feb 10, 2022	BUY	$4.6 - $6.72 $5,299 - $7,741	1,152 Added 4.41%	27,287 $124,000
Q3 2021 Nov 12, 2021	BUY	$5.58 - $7.04 $145,833 - $183,990	26,135 New	26,135 $164,000

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.15B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Viking Therapeutics, Inc. Transaction History